← Oncology Approval Tracker

FDA DECISION ·

Reblozyl

luspatercept-aamt · Celgene

FDA approvalNew or expanded indicationMyelodysplastic syndromes associated anemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with very low- to intermediate-risk MDS with ring sideroblasts or MDS/MPN with ring sideroblasts and thrombocytosis, whose anemia did not respond to an erythropoiesis-stimulating agent and required at least two red-cell units over eight weeks.

LAMPGEN ANALYSIS

Why it matters

Added an anemia treatment for a defined group with ongoing transfusion requirements.

What research teams should watch

Verify ring sideroblast classification and reconcile the rolling red-cell transfusion record before eligibility review.

PRIMARY RECORDS

Sources